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http://dx.doi.org/10.1016/j.jacl.2013.03Abstract: In humans, genetic variation occurs through different types of alleles that vary in frequency
and severity of effect. Mendelian mutations, such as those in the low-density lipoprotein (LDL) recep-
tor (LDLR) that result in familial hypercholesterolemia, are rare and have powerful phenotypic effects.
Conversely, alleles that are common in the population (such that homozygotes for the minor allele are
present even in modest sample sizes) typically have very modest phenotypic effects. In the middle of
the spectrum are ‘‘Goldilocks’’ alleles such as mutations in the gene for proprotein convertase subtil-
isin/kexin type 9 (PCSK9). Loss-of-function mutations in PCSK9 result in significantly decreased
LDL-cholesterol levels and a disproportionately large reduction in coronary heart disease risk by re-
ducing the exposure to LDL-cholesterol throughout life. Several agents to inhibit PCSK9 are currently
in development, demonstrating the potential utility of translating genetics into clinical therapeutics. To
date, most investigations aimed at identifying the genes responsible for hypercholesterolemia have used
linkage analysis, which requires samples collected from multiple families with defects in the same
gene, or common variant analysis which requires thousands of samples from the population. However,
case studies have shown that with advances in whole genome sequencing or exome sequencing (tar-
geted exome capture), the process of discovering causal genetic mutations can be significantly stream-
lined. Astute clinical observation of individual patients and their families with atypical lipid profiles,
followed by sequencing of the affected individual, has the potential to lead to important findings re-
garding the genetic mutations that cause lipid abnormalities.
 2013 National Lipid Association. All rights reserved.The studyofgenetics is primarily anexaminationofgenetic
variation, which in humans occurs through diverse alleles with
varying frequencies and effect sizes (Fig. 1). At one extreme
are mutations that cause Mendelian diseases such as familial
hypercholesterolemia (FH). arising from mutations in the
low-density lipoprotein (LDL) receptor gene (LDLR). and fa-
milial defective apolipoprotein (Apo) B. arising from defectsouthwestern.edu
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.005in the Apo B gene (APOB).1,2 These mutations are inevitably
rare and have powerful effects on phenotype. At the other end
of the mutation spectrum are common alleles, eg, the Apo E
(APOE) allele and variants in the sortilin 1 gene (SORT1).3,4
Thesevariations are characterizedby small phenotypic effects.
In the middle of the spectrum is a class of alleles termed
‘‘Goldilocks alleles.’’ The quintessential example of a Goldi-
locks allele is provided by the proprotein convertase subtili-
sin/kexin type 9 gene (PCSK9),5 which has mutations that
are common enough to be useful in epidemiological analyses,
in contrast to Mendelian alleles, but still produce readily de-
tectable effects in biochemical assays.s reserved.
Figure 1 Schematic of the relationship between allele frequency
and effect size. APOB, gene for apolipoprotein B; APOE, gene for
apolipoprotein E; LDL-C, low-density lipoprotein cholesterol;
LDLR, gene for low-density lipoprotein receptor; PCSK9, gene
for proprotein convertase subtilisin/kexin type 9; SORT1, gene
for sortilin 1.
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Mendelian alleles have traditionally been identified by
linkage studies in families. The classic example of FH is
shown in a pedigree in which two individuals with unusu-
ally high LDL cholesterol (-C) levels and mutations in the
LDLR married and produced two heterozygote children and
one homozygote with severe hyperlipidemia. Studies indi-
cate that w5% of patients who have had a myocardial in-
farction (MI) before 60 years of age have heterozygous
FH, and w50% of untreated FH heterozygotes will have
an MI by age 60.6,7 These results suggest that an isolated
high LDL-C level is sufficient to produce coronary heart
disease (CHD).
The genetics of FH were initially investigated in
Lebanon in the 1970s, before the era of molecular genetics,
when Khachadurian recognized that there was more than
one type of FH.8 The dominant form, where at least one
parent was affected, was well known, but another type of
FH was suspected in a family in which two parents with
normal LDL-C levels had four children with extremely
high LDL-C levels. To date, there are at least five known
dominant and recessive disorders of LDL metabolism.
Dominant disorders include FH caused by a mutation of
LDLR; familial defective Apo B caused by a defect in
APOB,9 which diminishes the ability of LDL to bind to
the LDL receptor; and FH type 3, caused by mutations in
PCSK9 which increase degradation of the LDL receptor.10
There are two well-defined recessive disorders of hy-
percholesterolemia: autosomal-recessive hypercholesterol-
emia (ARH) and sitosterolemia.11,12 ARH is caused by a
defect in the ARH gene, also known as the LDL receptor
adaptor protein 1 gene (LDLRAP1), which encodes an
adaptor protein that is required for localization of the
LDL receptor to clathrin-coated pits.12 In the absence of
functioning ARH, LDL receptors sit on the surface ofthe cell, where they can bind to LDL but are unable to
internalize it. Sitosterolemia is a disorder of neutral sterol
excretion characterized by an accumulation of plant
sterols. It is caused by mutations in two pumps, adenosine
triphosphate-binding cassette subfamily G member 5
(ABCG5) and member 8 (ABCG8), which together form a
complex that pumps neutral sterols out of enterocytes and
hepatocytes.11 Individuals with sitosterolemia have varying
degrees of hypercholesterolemia. All five of these dominant
and recessive disorders are significantly associated with
premature severe CHD, demonstrating that, irrespective of
cause, elevated LDL-C is a risk factor for CHD.
Common alleles
There is a great deal of interest in finding common
alleles that explain the differences in LDL-C levels in the
general population. Genome-wide association studies
(GWAS) examine many genetic variants to determine
whether any are associated with a trait, typically major
diseases or conditions like hypercholesterolemia. Results
from a monumental meta-analysis of GWAS evaluating
more than 100,000 individuals indicated that there are at
least 95 different loci in the human genome that are
systematically associated with plasma lipid and lipoprotein
levels.4 However, essentially all of these effects are small
individually, and cumulatively these sequence variations
explain only a small fraction of the variation in LDL-C
or high-density lipoprotein (HDL)-C levels.
There are pros and cons of GWAS.13,14 In many cases the
effects of the variants identified are small and difficult to inter-
pret biologically.On theother hand, theymay reveal genes that
are not amenable toMendelian genetics. For example, it’s un-
likely that a Mendelian defect in 3-hydroxy-3-methylglutaryl
coenzymeA (HMG-CoA) reductase, the rate-limiting enzyme
in cholesterol biosynthesis, will ever be detected because no
cell can live without HMG-CoA reductase. Yet more subtle
mutations or variations HMG-CoA reductase have been cap-
tured by a GWAS in the general population.
Epidemiological investigations have demonstrated a
strong positive correlation between increased LDL-C and
increased risk for CHD and a negative correlation between
HDL-C and CHD risk.15 However, this correlation, although
highly consistent, does not prove that low HDL-C causes
CHD. Although there is a significant body of evidence point-
ing to the causality of high LDL-C and CHD, whether a high
HDL-C concentration per se protects fromCHD is unclear.16
To demonstrate causality, investigations are needed that as-
sess whether sequence variations that systematically confer
either a high HDL-C or a low HDL-C level, absent of any
other change in the lipoprotein profile, are associated with
CHD. In a Mendelian randomization analysis of data from
prospective studies, Voight et al analyzed multiple variants
affecting HDL-C levels and their correlation with CHD.17
Using a genetic score of common polymorphisms associated
with LDL-C as a positive control, they found that a genetic
score based on gene sequence variations that increased
Cohen Emerging LDL therapies: human genetics S3HDL-C levels was not significantly associated with reduced
risk of MI (odds ratio [OR] per SD increase in HDL-C due to
HDL-C genetic score 0.93, 95% confidence interval [95%
CI] 0.68-1.26, P 5 .63; Fig. 2).17 These data support the ar-
gument that HDL-C is not causally related to CHD.Although
it is clearly associated, HDL-C ismore likely amarker for the
disease process than a direct cause thereof. Notably the esti-
mate from observational epidemiology that a one standard
deviation increase in LDL-C was associated with increased
risk for MI was concordant with that determined from the
LDL-C genetic score (OR 2.13, 95% CI 1.69–2.69, P 5 2
! 10[210]), supporting the theory that genetic mechanisms
that increase LDL-C translate directly into increased MI.17Goldilocks alleles–PCSK9
PCSK9 was initially implicated in lipoprotein metabo-
lism when PCSK9 mutations were found in two families
with autosomal-dominant hypercholesterolemia but normal
LDLR alleles. Studies in mice revealed that these mutations
were, in fact, gain-of-function. An examination of the low
end of the LDL-C distribution in the Dallas Heart Study
found that a significant fraction of individuals had mutations
in PCSK9.5,18,19 These were loss-of-function mutations. Ap-
proximately 2% of the African Americans evaluated had
one loss-of-function allele in PCSK9 that lowered LDL-C
by 40%. Among European Americans, w3% had a less
severe mutation that resulted in 21% lower LDL-C levels.
An examination of the Atherosclerosis Risk in Commu-
nities population showed that among African Americans,
the average LDL-C reduction in carriers of the PCSK9 mu-
tation (heterozygotes) was 28%. This finding was associ-
ated with an 88% reduction in incident CHD during a
period of 15 years.5 In European Americans, the LDL-C re-
duction was 15%, leading to a 46% reduction in CHD. Of
note, more than half of the African Americans studied were
hypertensive, one-third smoked, and almost 20% hadFigure 2 Hazard ratios of myocardial infarction in prospective
studies (n 5 25,000) per standard deviation increase in lipid level.
Plasma denotes predicted hazard ratios for the change in plasma
levels of each lipoprotein that would be caused by the SNPs.17
HDL, high-density lipoprotein; LDL, low-density lipoprotein;
SNPs, single nucleotide polymorphisms.diabetes (risk factors that occurred with the same frequency
in mutation carriers and noncarriers). Nonetheless, the
PCSK9 mutation conferred marked protection from CHD
up to w70 years of age, the upper age limit of the study
participants at the time of screening.
Themagnitude of protection against CHDprovided by the
lower LDL-C level observed in those with PCSK9 loss-of-
function mutations in the Dallas Heart and Atherosclerosis
Risk in Communities studies is greater than might be
expected based on results from statin trials.20,21 This discrep-
ancy holds true in other populations and is not peculiar to
PCSK9. Variants such asAPOB, SORT1, and LDLR also con-
fer a disproportionate increase in CHD risk protection rela-
tive to the level of LDL-C, based on predictions from statin
trials (Fig. 3).1,22 The reason for this may be that genotypes
capture another dimension–time. The phenotype of LDL-C
concentration gives a snapshot of the cholesterol concentra-
tion at the present time, but genotypes integrate the ‘‘ten-
dency’’ of an individual’s LDL-C concentration since birth.21
Pragmatically, it appears that complex diseases, partic-
ularly CHD, may not actually be so complex. In the case of
CHD it is clear there is a single predominant risk factor.
Although the value of other risk factors should not be
ignored, the cardinal risk factor is high LDL-C concentra-
tion combined with the amount of time the patient has been
exposed to increased LDL-C (or atherogenic LDL parti-
cles). A measure of cumulative exposure, analogous to
pack-years for smokers, would provide a more accurate
prediction of risk of CHD. Currently, therapeutic steps are
not taken until an individual has an increased 10-year risk
beyond some threshold; typically, this involves a delay in
treatment until patients are at least 50 years of age.15 Ge-
netic data suggest that starting treatment earlier might pro-
duce ‘‘more bang for the therapeutic buck,’’ whether that
therapy is diet or statins.
Early experiments raised considerable interest in the
utility of PCSK9 for LDL-C-lowering and CHD prevention,Figure 3 Reduction in coronary heart disease associated with
LDL-C lowering according to gene variants or statin use.1,22
APOB, gene for apolipoprotein B; CHD, coronary heart disease;
LDL-C, low-density lipoprotein cholestrol; LDLR, gene for
low-density lipoprotein receptor; PCSK9, gene for proprotein con-
vertase subtilisin/kexin type 9; SORT1, gene for sortilin 1.
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PCSK9, particularly because it is expressed in several tissues
in addition to the liver (eg, kidneys, brain). To investigate
whether the absence of PCSK9 would be compatible with
good health, family members of individuals in the Dallas
Heart Studywith a singlemutation inPCSK9were identified.
In one of these families, the proband was a 53-year-old
woman with an LDL-C level of 49 mg/dL. Her 32-year-old
daughter had an unusually low LDL-C level (14 mg/dL).23
The daughter had inherited her mother’s mutation in
PCSK9, Y142X,which is a premature stop code in the protein
transcript, and another mutation from her father, which de-
leted an arginine at codon 97. For practical purposes, these
mutations rendered both copies of the gene nonfunctional, re-
sulting in total deficiency of PCSK9. The deficiency in
PCSK9 did not appear to have any adverse effects. Her intel-
ligencewas normal (shewas a college graduate); she had nor-
mal kidney and liver functions and normal blood pressure.
PCSK9 is expressed at fairly high levels in the cerebellum,
particularly during development, but neurological examina-
tion and magnetic resonance imaging results, plus her voca-
tion as an aerobics instructor, confirmed that the PCSK9
deficiency did not adversely affect her motor control. A
follow-up 6 years later verified that after nearly 40 years of
total absence of PCSK9 and extremely low LDL-C (14–29
mg/dL), this individual continued to be in good health. Sub-
sequently, a 21-year-old pregnant Zimbabwean woman was
identified as a compound heterozygote with two PCSK9mu-
tations.24 Little is known about this patient, other than she
had an extremely low LDL-C level (16mg/dL) when she vis-
ited an antenatal clinic.
The culmination of these genetic efficacy and safety
studies has been the development of agents designed to
inhibit PCSK9. It has proved difficult to target PCSK9 with
small molecules, but several companies have developed
monoclonal antibodies that inhibit PCSK9. The results of
the first trial demonstrated that inhibition of PCSK9 caused a
sharp, prompt, and relatively isolated reduction in LDL-C,
without obvious side effects, exactly as would be predicted
from the genetics.25 The rapid course of this work illustrates
the utility of genetics in the development of therapeutic
agents. From the initial discovery to clinical trials has taken
seven years: the initial discovery of PCSK9 in 2003 to the
discovery of LDL-C-lowering variants in the gene and target
validation and completion of phase 1 trials 4 years later.
Several trials of PCSK9 inhibitors are now in progress.Whole-genome sequencing
New developments in sequencing technology have made
it possible to screen the entire genome (or exome), poten-
tially allowing the identification of disease-causing muta-
tions in novel genes in individual patients. The power of this
approach for patients with lipid disorders was illustrated by
the discovery of a family with atypical hypobetalipopro-
teinemia in which four of the offspring had very low levels ofLDL-C, HDL-C, and triglycerides. These individuals were
distinguished from carriers of typical APOB mutations that
prevent secretion of very low-density lipoprotein because
they did not have steatosis, which almost invariably occurs
in individuals with conventional familial hypobetalipopro-
teinemia.26 Exome sequencing revealed that the affected off-
spring were homozygous for a mutation in ANGPTL3, a
gene which encodes angiopoietin-like 3—an inhibitor of
lipoprotein lipase and endothelial lipase.27 This finding dem-
onstrates that astute clinical observation of individual
patients and their families with atypical and unexplained
lipid profiles, followed by sequencing of the affected indi-
viduals, has the potential to provide major new insights
into the molecular basis of lipid diseases.
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